REBECCA POWELL: Open Payments
NPI 1770258790 · FLORENCE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$734 in 16 payments from 11 companies in 2025. Trend: 2023 $579 · 2024 $341 · 2025 $734
Food & beverage: $734
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $160 |
| Teva Pharmaceuticals USA, Inc. | 2 | $141 |
| Luye Pharma (USA) Ltd. | 1 | $129 |
| Axsome Therapeutics, Inc. | 1 | $106 |
| ABBVIE INC. | 2 | $63 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Alkermes, Inc. | 1 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
Products named: CAPLYTA, AUSTEDO XR, ERZOFRI EXTENDED-RELEASE, Auvelity, VRAYLAR, REXULTI, Jornay PM, ARISTADA.
Industry payments across KY — which companies pay providers there.
